JDRF would love to hear from you about our first-ever digital annual report. Please share your feedback with us!
Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).
Researchers at the University of Alberta have reported that a two-drug combination, sitagliptin and pantoprazole, can restore insulin independence in some islet transplant recipients with early signs of transplant failure. The effect was not sustained after withdrawal of the drugs; there was lack of evidence for durable effects on beta cell function or increased beta cell mass. JDRF continues to support research to improve long-term islet transplant function and to promote beta cell regeneration in all people with T1D.
In the JDRF-funded Medalist Study of individuals who have lived with T1D for at least 50 years, researchers have discovered that some Medalists are protected from advanced diabetic retinopathy because they have a slow rate of retinopathy onset or progression. Further, after 20 years of T1D, progression of retinopathy appears to halt. Researchers can now search for factors that mediate this slow disease progression and exploit them to develop new strategies to prevent or treat diabetic retinopathy.
A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.
Question: I recently married and moved to a new area. I found a physician for type 1 diabetes (T1D) care and checked his credentials, and he seems good “on paper.” But is there a checklist of questions I can ask to gauge whether this is the right physician for me? Answer: First, congratulations on this […]
I am excited to bring this new issue of Countdown to our readers. It is an issue that speaks profoundly to the core mission of JDRF—research. At the heart of what we do is our dedication and commitment to discover, develop, and deliver advances that cure, better treat, and prevent type 1 diabetes (T1D). As we work […]
Countdown is written and produced by our Marketing and Communications team here at JDRF. As the leader of the team and JDRF’s chief marketing officer, I am pleased to bring our new issue to you. We have so much news and information to share—and it is our hope that you will share it with everyone you […]
By Jeffrey Brewer When JDRF was asked to submit an article to Diabetes, a medical journal of the American Diabetes Association (ADA), our organization’s leaders recognized the superb opportunity offered by this request. As a result, “Juvenile Diabetes Research Foundation: Mission, Strategy, and Priorities” was published in the January 2012 issue ofDiabetes in the journal’s “Perspectives in […]
Researchers supported by JDRF recently characterized for the first time the nature of the encounter between killer T cells and their targets—the insulin-producing beta cells in the pancreas. Using an actual T cell that was replicated or “cloned” from a patient with type 1 diabetes (T1D), the
researchers provided valuable evidence about the interaction that takes place on a molecular level and contributes to the autoimmune attack that destroys beta cells. These findings can help guide the development of targeted therapies for the prevention of T1D.